HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
Studying the Clinical Course of Risankizumab
This study is now recruiting.
Risankizumab is a medication used for the treatment of Crohn's Disease in adults and children to limit symptoms of the disease. However, as children differ more than adults in their age/weight range and the way that drugs move around their body, more information is needed to understand the factors that might affect the response to the drug in children.
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at nagarkattm [at] chop.edu or 267-591-5232.
Eligibility & Criteria
IRB #:
24-021971
Official Title:
Risankizumab in Children with Crohn's Disease: A Multi-Center PORTO Group Prospective Study
Study Phase:
Not Applicable
Eligible Age Range:
1 Months - 17 Years
Gender:
All
Study Categories:
Visit Criteria
Participation will last for approximately 3 years and involve 8 study visits. Each visit will include a study questionnaire and a physical examination, if one was not completed at a recent office visit. The study team will also look through participants' medical records for demographic, medication, and disease activity data.
Leader
